Secondary prevention medications are often not prescribed to frail, older adults following acute myocardial infarction, potentially because of the absence of data to support use, perceived lack of benefit, and concern over possible harms. We examined the effect of using more guideline-recommended medications after myocardial infarction on mortality, rehospitalization, and functional decline in the frailest and oldest segment of the US population-long-stay nursing home residents.
A cute myocardial infarction (AMI) remains a major cause of morbidity and mortality in the United States, with about 790 000 Americans experiencing a new or recurrent AMI every year. 1 Four classes of medication are recommended by guidelines [2] [3] [4] for the secondary prevention of AMI: antiplatelets, β-blockers, statins, and renin-angiotensin-aldosterone system inhibitors. Each of the 4 medication classes improves clinical outcomes when initiated post-AMI. [5] [6] [7] [8] With the average age of first AMI being 65.3 years for men and 71.8 years for women, older adults represent a large portion of patients requiring secondary prevention medications. 1 Optimal use of these medications has a proven mortality benefit post-AMI in older community-dwelling adults. 9, 10 While understanding the risks and harms of individual medication classes after AMI is important, focusing on the total number of medications prescribed captures additional information about the outcomes associated with overall intensity of treatment. It also provides a greater understanding of the cumulative benefits and risks that can occur when multiple medications are used in the same patient, which can lead to complex interactions between drugs and with the patient's physiology. 11 These issues are of special importance for older adults in late life, in whom polypharmacy and debate over the risks and harms of intensive treatment are central issues. 11 Frailty is the decreased ability of individuals to recover from physiological insults and often presents with the phenotype of weight loss, sarcopenia, or the lack of independence in activities of daily living (ADL). [12] [13] [14] Secondary prevention medications are often not prescribed to frail, older adults, especially those residing in the nursing home (NH) long-term, which is the frailest and oldest subpopulation in the United States. [15] [16] [17] The lack of prescribing may be, in part, because of perceived lack of benefit, concern over potential harms, and lack of data as NH residents are rarely included in clinical trials of medications. 16, 17 Given the deviations from clinical guidelines for older adults in the NH setting, understanding how these medications affect outcomes in the NH population may influence and optimize future prescribing. Data on how treatment effects vary across subgroups defined by age, cognition, and functional status (proxies for life expectancy) would be particularly useful to guide prescribing since older, frailer individuals may benefit less from receiving more secondary prevention medications.
We examined the association between prescribing more versus fewer guideline-recommended medications post-AMI in older NH residents and functional decline, mortality, and rehospitalization outcomes. Our investigation can help inform whether prescribing fewer medications is appropriate in frail older adults because of the limited life expectancy and other relevant characteristics of the population. Furthermore, it can help identify which groups would be most likely to benefit from receiving more secondary prevention medications after AMI.
METHODS

Study Design and Data Sources
The data are subject to a data use agreement with the Centers for Medicare and Medicaid Services and cannot be made available to other researchers for purposes of reproducing the results or replicating the procedures.
This was a retrospective new-user cohort study that linked the following national datasets: Medicare fee-for-service denominator (eligibility) information, Medicare Part A inpatient hospital claims, Medicare Part D prescription drug claims, and Minimum Data Set (MDS) 2.0. The MDS is a comprehensive, clinical assessment instrument used to document health status of NH residents, including demographic, medical, functional status, psychological, and cognitive status information. The MDS assessments are federally mandated for all residents in NHs certified to receive Medicare or Medicaid funding. Online Survey Certification and Reporting data were used for facilitylevel information, including NH characteristics, staffing levels, and quality measures. A previously validated algorithm was used to track the timing and location of health service use.
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Study Population
The study population was a previously established 16, 17, 19, 20 national cohort of long-stay NH residents aged ≥65 years
WHAT IS KNOWN
• Four classes of medication are recommended for the secondary prevention of acute myocardial infarction and have a mortality benefit in nonfrail, older adults: antiplatelets, β-blockers, statins, and renin-angiotensin-aldosterone system inhibitors.
• Secondary prevention medications are often not prescribed to frail, older adults, especially those residing in nursing homes long-term. Prescribing fewer medications is due, in part, to perceived lack of benefit, concern over potential harms, and lack of supporting data.
WHAT THE STUDY ADDS
• Prescribing 3 or 4 secondary prevention medications to predominantly frail, older adults was associated with a 26% relative decrease in mortality compared with individuals who received 1 medication after acute myocardial infarction, but no notable difference in all-cause rehospitalization, and effects did not differ by age, sex, race/ethnicity, cognition, or functional status.
• Use of more secondary prevention medications was associated with a 30% relative increase in functional decline after excluding antiplatelet drugs from the exposure definition but not when considering all medications. Figure I in the Data Supplement). Long-stay NH residents are a predominantly frail population, thus we did not apply specific inclusion criteria to isolate long-stay residents that met a particular definition of frailty. However, we excluded patients with extremely poor functional status before the AMI hospitalization (ADL score ≥24) because they had little opportunity for further functional decline (see Outcomes below). 19, 21 We selected previous nonusers to permit an evaluation of the decision to initiate secondary prevention medications after AMI, distinct from the decision to continue these agents in patients who had already been taking them before their AMI. Additional details of the cohort have been previously described. 16, 17, 19 
Exposure and Contrasts of Interest
Oral antiplatelet, β-blocker, statin, and renin-angiotensinaldosterone system inhibitor medications, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (Table I in the Data Supplement), were identified according to generic name in Medicare Part D prescription drug claims. 22 The categorical secondary prevention medication use variable had 3 distinct levels: 1, 2, and 3 or 4 medication classes used. There were few individuals who received 4 medications, so they were grouped with those who received 3 medications. Individuals who received zero medications were excluded to minimize confounding bias because they represent a distinct group from all others. These individuals tend to be much sicker and less likely to benefit from medications, so significant confounding by prognosis is a concern for any comparisons with them. The effects of different combinations of medication classes were not examined because the sample size precluded such analyses, and the focus of this study was on the potential value associated with prescribing more guideline-recommended medications (ie, increasing medication burden).
The contrasts of interest were defined as the effect of initiating 3 or 4 versus 2 versus 1 secondary prevention medications in the immediate post-AMI period, regardless of subsequent treatment discontinuations, switches, or additions among the treatment groups (ie, the intention-to-treat estimand). [23] [24] [25] This is analogous to emulating a multiarm pragmatic trial that compares the incremental benefits and harms of more versus less guideline-concordant prescribing.
Outcomes
The 3 outcomes were death, all-cause rehospitalization, and functional decline. We used data from Medicare Part A and Medicare enrollment files to identify hospital admissions and date of death. Functional decline was defined as an increase of 3 points on the validated 28-point MDS Morris scale of independence in ADL between the prehospital baseline assessment and the first available assessment after hospitalization up to 3 months after discharge. 21, 26 This measure indicates the degree of dependence on staff assistance in 7 areas of ADL function (bed mobility, transfer, locomotion, dressing, eating, toilet use, and personal hygiene), which are summed to create a validated score that ranges from 0 (no assistance required) to 28 (total dependence in ADL functioning). 21 Increases in this score over time have been validated as an important marker of functional decline, and a 3-point increase corresponds to a major loss of independence in one ADL or incremental losses in 2 or more ADLs.
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Follow-Up
We excluded individuals who died or were hospitalized within 14 days of hospital discharge because reliable ascertainment of secondary prevention medication use is difficult in such short-stay situations. Follow-up, therefore, started on day 14 (index date) after hospital discharge and continued for 90 days. 19 For the rehospitalization outcome, at the end of the 90-day follow-up, participants were classified as alive without rehospitalization, having had a rehospitalization, or having died without a rehospitalization. For the functional decline outcome, at the end of the 90-day follow-up, participants were classified as alive without functional decline, having had functional decline documented on an MDS assessment in that period, or having died without evidence of functional decline on the MDS. For the death outcome, individuals were simply categorized as alive or dead at 90 days.
Baseline Characteristics
Variables that could potentially confound the relationship between the number of secondary prevention medications prescribed and outcomes were prespecified and all measured before the index date. A complete list of these 89 characteristics and details about their measurement are provided in Table  II in the Data Supplement.
Statistical Analyses
We adjusted for confounding by baseline covariates using methods that rely on estimating the propensity score (ie, the joint probabilities of receiving 2 medications versus 1 and 3 or 4 medications versus 1, conditioned on covariates). We estimated the propensity score via a multinomial logistic regression model that used the aforementioned 89 baseline variables (Table II in the Data Supplement) to predict the number of secondary prevention medications used. The propensity scores were used to construct stabilized inverse probability of treatment weights (IPTWs), which resulted in good covariate balance across treatment groups based on standardized mean differences (Table III in the Data Supplement) .
We used IPT-weighted binomial logistic regression models to estimate odds ratios (ORs) and 95% CIs comparing more versus less secondary prevention medication use for the outcome of death. We used IPT-weighted multinomial logistic regression models for the rehospitalization and functional decline outcomes to account for the competing risk of death. 27 In all outcome models, use of 1 medication was the reference exposure level.
We conducted several stability analyses (eg, IPTW truncation; exclusion of antiplatelet users from treatment definition) to test the robustness of our treatment effect estimates to analytic decisions (Data Supplement). In one stability analysis, we excluded users of antiplatelet agents because aspirin is a recommended antiplatelet agent (in addition to clopidogrel, or more rarely, as an alternative) but is available without a prescription and thus underascertained in Medicare claims, which could result in biased estimates.
We considered P<0.05 to be statistically significant.
Subgroup Analyses
In separate analyses to evaluate whether the association between prescribing more versus less secondary prevention medications and outcomes varied across participant characteristics (ie, effect measure modification 28 ), we included interaction terms between the exposure and characteristic (ie, multiplied the 2 independent variables). These baseline characteristics included levels of age (≤85 versus >85), 29 cognitive function (moderate to severe impairment versus no to mild impairment), and functional status (moderate to severe impairment versus no to mild impairment). We also examined sex and race/ethnicity, though these subgroup characteristics were of secondary interest. The IPTWs were reestimated for subgroup analyses to ensure covariate balance between treatment groups within subgroups, which was examined using standardized mean differences.
Software
Data were analyzed using SAS, version 9.4 (SAS Institute, Inc, Cary, NC) and Stata, version 14.0 (Stata Corp, College Station, TX), software.
Ethics Approval
The institutional review boards of Brown University, the University of California San Francisco, and the San Francisco VA Health Care System approved the study protocol.
RESULTS
Study Cohort
Our study cohort included 4787 NH residents, of which 1825 (38.1%) received 1 medication, 1572 (32.8%) received 2 medications, and 1390 (29%) received 3 or 4 medications post-AMI ( Figure I in the Data Supplement). The different combinations of medication classes are shown in Table IV in the Data Supplement. The mean (SD) age of the study cohort was 84 (8) years and the majority were female (n=3269; 68%) and white race (n=4014; 84%). Approximately 50% of the cohort had moderate to severe cognitive impairment (n=2373) and 74% of the cohort required extensive or greater assistance with their ADLs (n=3542). On average, residents were actively taking 11 medications (SD=5). Hypertension (n=2706; 56.5%) and heart failure (n=2437; 50.9%) were the most common chronic conditions. The median pre-AMI length of NH stay was 352 days (interquartile range 81-1081).
The prevalence of baseline characteristics by treatment group is shown in Table 1 and accompanying standardized differences in Table III in the Data Supplement. Age differed markedly across treatment groups before IPT weighting, with older NH residents being less likely to receive more secondary prevention medications. Residents receiving fewer secondary prevention medications were also less likely to have hyperlipidemia, diabetes mellitus, or hypertension but were more likely to have atrial fibrillation. Notably, residents receiving more medications had a better functional status, less severe cognitive impairment, and shorter pre-AMI lengths of NH stay.
During follow-up, 509 of 4787 participants died (10.6%), 820 (17.1%) experienced a functional decline event, and 1226 (25.6%) were rehospitalized.
Outcomes of Secondary Prevention Medication Use
Prescribing 3 or 4 medications was associated with a significant decrease in mortality compared with patients who received 1 medication post-AMI (OR, 0.74; 95% CI, 0.57-0.97) but no significant difference in functional decline (OR, 1.12; 95% CI, 0.89-1.40) or allcause rehospitalization (OR, 0.97; 95% CI, 0.80-1.17; Table 2 ). Prescribing 2 medications instead of 1 was not associated with significant decrease in mortality (OR, 0.98; 95% CI, 0.79-1.22), functional decline (OR, 1.04; 95% CI, 0.85-1.28), or rehospitalization (OR, 1.00; 95% CI, 0.85-1. 19 ).
Treatment Effects in Subgroups
In a subgroup analysis stratifying patients by age >85 or ≤85 years, no notable differences were observed for the associations between more versus less secondary prevention medications and mortality, rehospitalization, or functional decline outcomes (Table V in the Data Supplement). No significant differences were observed for any outcome between treatment groups when patients were stratified on their cognitive performance (Table 3 ) or functional status (Table 4) at baseline. No sex-or race/ethnicity-based differences were observed (data not shown).
Stability Analyses
Weight truncation did not meaningfully alter the results (Table VI in 
DISCUSSION
In this national retrospective cohort study, we found that the use of more guideline-recommended secondary prevention medications post-AMI was associated with a decrease in mortality in older, predominantly frail residing in NHs. Residents receiving 3 or 4 secondary prevention medications had a 26% lower risk of mortality compared with residents receiving 1 medication. Use of more guideline-recommended medications did not appear to influence the risk of rehospitalization. The main and stability analysis results for functional decline were discordant and suggested that more medication might be associated with an increased risk of functional decline. The associations between secondary prevention medication use and outcomes did not markedly vary across subgroups defined by age, cognitive status, or functional status. Prior studies have demonstrated that less prescribing of secondary prevention medications is common among older NH residents and may be attributable to the absence of data demonstrating the benefits of using more guideline-recommended medications after AMI in NH residents. 16 Our findings suggest that prescribing more guideline-recommended medications is indicated for frail, older adults who wish to maximize longevity after AMI. 19, 30 †Scores ranging from 0-5, with higher scores indicating greater health instability. Although data on the use of more versus fewer secondary prevention medications in frail, older adults are lacking, our study is consistent with 2 studies using older data to examine the associations between secondary prevention medications and mortality in older community-dwelling adults. 10, 31 The non-US populations in these studies are younger and much less frail than our population of NH residents. However, they offer the most comparable published data to our own, highlighting the severe lack of information on the effects of using more secondary prevention medications among frail, older adults. The first study demonstrated that individuals receiving all 4 medication classes, or 3 if a fourth class was contraindicated, had significantly lower 1-year mortality compared with participants receiving 0 or 1 medications at discharge (adjusted OR, 0.54; 95% CI, 0.36-0.81). 10 The second study suggested that the use of all 4 guideline-concordant medications is associated with decreased mortality compared with 0 medications (hazard ratio, 0.40; 95% CI, 0.21-0.95). 31 Little is also known about the effects of individual cardiovascular medication classes in highly vulnerable old- IPTW indicates inverse probability of treatment weights; and OR, odds ratio. IPTW indicates inverse probability of treatment weights; and OR, odds ratio. *Measured by the Cognitive Performance Scale and dichotomized as 0 to 2 (intact cognition to mild impairment) and >3 (moderate to severe impairment). †Presented for the IPTW estimates only.
er adults, but our findings are generally consistent with another study that found new use of β-blockers versus nonuse after AMI was associated with a mortality benefit (hazard ratio, 0.74; 95% CI, 0.67-0.83) among older NH residents. 19 Our study contributes to the literature on more versus less secondary prevention medication use by studying a much frailer and older population than has been previously examined. It does so with more recent data, a larger and nationally representative US sample, a richer set of covariates, and functional and rehospitalization outcomes for which data was not previously available. Additionally, to provide data that helps providers to tailor treatment decision-making to individual patients, we performed subgroup analyses by patient-specific factors that are associated with life expectancy, including age, cognition, and functional status at baseline. Ultimately, we found that the association between more secondary prevention medication use and outcomes did not markedly vary across subgroups defined by age, cognition, or functional status at baseline. In our study, individuals who were older, cognitively impaired, and functionally dependent were all still likely to derive a mortality benefit from being prescribed more secondary prevention medications after AMI, which agrees with prior literature on β-blockers in the same population of older NH residents. 19 These results support the conclusion that the average time to mortality benefit associated with prescribing more medications may be shorter than the average life expectancy of many NH residents after AMI. 32, 33 In turn, the results support prescribing more secondary prevention medications post-AMI for older, predominantly frail adults who wish to maximize their longevity. However, for older adults who do not wish to maximize longevity, our results also highlight an opportunity to reduce polypharmacy through deprescribing-the process of tapering or stopping medications under medical supervision. 11 Despite the possibility that using more medications provides a mortality benefit, it is important to weigh the potential risks, several of which are unexaminable in our data. Use of more secondary prevention medications increases polypharmacy for older adults while increasing the complexity of medication management for caregivers, including NH staff. Taking more medications may also increase the risk of drug-drug interactions and adverse drug events. For example, the use of more guideline-recommended medications after an acute coronary syndrome was associated with greater risk of falls among women who were frail but not among those who were robust. 9 While the time to mortality benefit of taking more secondary preventions may be weeks to months, the risk of drug-drug interactions and adverse events may increase in just hours to days. This is especially true among NH residents because of the altered pharmacokinetics and pharmacodynamics that arise with advanced age and frailty. 34, 35 Potential and empirically unverified risks of using more medications should not be an absolute barrier to prescribing in frail, older adults. Rather, the potential risks should be considered in the harm-benefit calculus before prescribing, monitored for, and appropriately managed if they arise (eg, through deprescribing or dose reduction). 36 The findings of our study must be interpreted in light of several limitations. First, because our study was observational, we cannot rule out the possibility of residual confounding. One plausible mechanism for confounding is that individuals with a more severe AMI are likely to receive a greater number of secondary prevention medications because of the stronger perceived indication for aggressive management. Another plausible mechanism is that individuals who were frailer, had a worse prognosis, or were generally sicker were less likely to receive more secondary prevention medications because providers perceived extensive treatment as futile. However, several factors support the robustness of our findings. The 2 proposed overarching mechanisms of confounding would bias results in opposite directions and thus cancel, at least in part. We also obtained good balance on almost 90 measured baseline covariates across treatment groups after IPTW. Furthermore, in prior work, we conducted a companion validation study using national data from the Department of Veterans Affairs, which contains information on vital signs, laboratory test results, and measures of cardiac function that was missing from our linked Medicare and MDS data. 19 That work suggested that these variables would not substantially alter the observed results.
A second limitation is that the inclusion of reninangiotensin-aldosterone system inhibitors may have increased residual confounding because they are indicated after AMI primarily for patients with heart failure, left ventricular systolic dysfunction, hypertension, and diabetes mellitus.
3,37 Although we adjusted for most of those variables in our propensity score estimation models, residual bias because of missing ejection fraction information is still a concern. Similarly, we were unable to accurately differentiate ST-segment-elevation MI from non-ST-segment-elevation MI, which may have influenced the prescribing of more versus fewer secondary prevention medications.
Third, because of the nature of our data, we were unable to conduct analyses of medication dose (eg, statin intensity), to examine some other outcomes that were of interest (eg, cognition), to assess etiologically relevant follow-up periods beyond 90 days, to include aspirin use in the exposure definition, or to examine the effect of different combinations of medication classes. Future studies should aim to address those important questions. Finally, sample sizes for many subgroups were limited in this study and thus a barrier to detecting small or moderate magnitude effects. Our larger (N=10 992) prior study suggested that the effects of β-blockers on functional decline differed significantly across subgroups. 19 
CONCLUSIONS
In summary, the use of more guideline-recommended medications post-AMI was associated with decreased mortality in older, predominantly frail adults, but no difference in rehospitalization. The mortality benefit was consistently observed across subgroups defined by baseline age, cognition, and functional status. Results for functional decline were discordant and did not rule out an increased risk associated with more medication use. Additional research is necessary to evaluate whether more secondary prevention medication use among frail, older adults truly does result in functional harms and how information on type of infarct may influence the results. While residual confounding remains a concern and plausible alternative explanation for all findings, the results suggest that use of more secondary prevention medications after AMI is indicated for frail, older adults who wish to maximize their longevity.
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